Subscribe to our news feed
A question?
11-04-2024
Getinge receives EU MDR approval of Advanta V12 covered stent system with use for patients with renal artery stenosis and/or aortoiliac occlusive disease
Getinge announces the EU MDR certification of its Advanta V12 covered stent system, highlighting its use for patients with aortoiliac occlusive disease, including lesions at the aortic bifurcation. This approval affirms the system's compliance with European Union medical device regulations and aligns its application, reflecting Getinge's commitment to quality and patient safety.
28-03-2024
Getinge extends the bioreactor portfolio with larger single-use systems
Getinge is extending its bioreactor offering by introducing the Single-Use Production Reactor (SUPR) system, which initially is available in 50-liter and 250-liter sizes. Based on the same proven platform as Getinge’s smaller bioreactors, the SUPR system helps operators to bring life-saving medicines faster to market, aiming to improve people’s quality of life.
28-03-2024
Getinge donates life-saving medical equipment to Ukraine
In a time where medical assistance is critical, Getinge donates extensive medical equipment to Ukraine. The donation, made in collaboration with the Ministry of Health Ukraine, includes a significant number of anesthesia machines and ventilators, aimed at directly improving healthcare and increasing the country's resilience against the challenges of war.
27-03-2024
Getinge publishes 2023 annual report
Today, Getinge publishes its 2023 annual report including a sustainability report, summarizing a year of huge contrasts. The global medtech company’s 2023 was marked by record-breaking sales, two major acquisitions, and successful product launches, amid the continued war in Europe, quality challenges in two product segments, and persistent inflationary pressure.
25-03-2024
Getinge and CellRev launch platform with potential to transform allogeneic cell therapy manufacturing
Getinge has partnered with the bioprocessing company CellRev in the development of a continuous cell processing platform called Livit ACE (Adherent Cell Expansion). The solution, launching today, is a breakthrough within allogenic cell therapy manufacturing.
Press Contacts
Lars Mattsson
Interim EVP Brand & Communication
Phone: +46 10 335 0043
Caroline Örmgård
Head of Public & Media Relations
Phone: +46 10 335 0041
Contact us online
Click below to fill in the appropriate form. We will be in touch shortly.
Are you looking for
Image Gallery
Diverse picture format made available for press article purpose
About us
All you need to know about Getinge a one glance
Urgent Medical Device Correction
Voluntary Urgent Medical Device Field Correction for the CARDIOSAVE intra-aortic balloon pump (IABP)
Don't miss anything
Click on the icons and follow us!